Cristina García-Herce

Cristina García-Herce

Auto-generated profile, based on publicly available information

Cristina García-Herce

16Department of Hematology, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Blood Advances
Verified
Journal Article
Open access
ÁSÁngel Serna
Ángel Serna
VGVictor Navarro Garcés
Victor Navarro Garcés
MJMoraima Jiménez
Moraima Jiménez
JIJosu Iraola-Truchuelo
Josu Iraola-Truchuelo
MBMarc Bosch
Marc Bosch
PAPau Abrisqueta
Pau Abrisqueta
Despite advances in vaccination and the use of antiviral treatments, patients with hematologic malignancies, including B-cell lymphoproliferative disorders, are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The recent introduction of bispecific antibodies (BsAbs) in the treatment algorithm of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) has raised concerns regarding their impact on COVID-19 outcomes. This study aimed to evaluate the impact of SARS-CoV-2 infection on treatment outcomes in patients receiving BsAbs. We assessed the severity of COVID-19 and SARS-CoV-2 serostatus, with antibody titers measured before, during, and after BsAbs administration. A total of 109 patients with B-NHL treated with BsAbs from March 2020 to January 2023 were included. SARS-CoV-2 infection was observed in 56 patients (51%), with 36% experiencing prolonged viral shedding, causing therapy delays in 78% of patients and permanent discontinuations in 19%. Regarding COVID-19 severity, 36% of patients presented moderate, 20% severe, and 12% critical disease. Seven patients (13%) died owing to COVID-19 pneumonia. Similar to observations with anti-CD20 monoclonal antibodies, BsAbs were associated with negative antispike serostatus for at least 6 months after treatment completion. Importantly, this lack of seroconversion was linked with severe disease and increased mortality. These findings underscore important considerations for the management of patients receiving BsAbs.

20 January 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
ÁSÁngel Serna
Ángel Serna
MBMarc Bosch
Marc Bosch
VNVíctor Navarro
Víctor Navarro
PLPatricia López‐Pereira
Patricia López‐Pereira
DQDavid Quintela
David Quintela
PAPau Abrisqueta
Pau Abrisqueta

30 October 2026 in Blood Advances
Verified
Journal Article
Open access
AMAnna Martín-Carrizosa
Anna Martín-Carrizosa
CGCristina García-Herce
Cristina García-Herce
DVDavid Quintela Vilchez
David Quintela Vilchez
JHJuan Carlos Caballero Hernáez
Juan Carlos Caballero Hernáez
RMRocio Figueroa Mora
Rocio Figueroa Mora
PAPau Abrisqueta
Pau Abrisqueta

16 October 2026 in Blood Advances
Verified
Journal Article
Closed access
Fernando Martin-MoroFernando Martin-Moro
Fernando Martin-Moro
AMAna Muntañola
Ana Muntañola
XGXabier Gutiérrez
Xabier Gutiérrez
MVMaría Sofía Vázquez
María Sofía Vázquez
LMLucía Morais
Lucía Morais
ASAntonio Salar
Antonio Salar
There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase 2 MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R/R MZL treated with zanubrutinib after at least 1 previous anti-CD20–based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), mucosa-associated lymphoid tissue (18.9%), nodal (19.8%), and nonclassifiable (6%). The median number of previous lines of therapy (LoT) was 1.5 (range, 1-7); 26% of patients had MZL refractory to the immediately preceding line, and 59% experienced progression of disease within 24 months (POD24) to frontline therapy. In total, 31 patients (26.3%) would not have met MAGNOLIA trial eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA trial eligibility. Fewer previous LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than those with progressing disease (P< .01). Adverse events (AEs) were reported in 34.1% of patients (grade ≥3 in 14.4%). MAGNOLIA trial–ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (P = .04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R/R MZL, with improved outcomes when administered earlier in the disease.